In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...
The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...
Medically reviewed by Gagandeep Brar, MD Key Takeaways CMML is a rare form of leukemia that can cause extreme fatigue, easy ...
Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...
To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B ...
Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool, called MARLIN (Methylation- ...
Unlock the potential for faster, more comprehensive leukemia characterization with this webinar from Dana-Farber Cancer Institute expert Salvatore Benfatto. Acute leukemia (AL) is an aggressive form ...
Researchers at Zhejiang University School of Medicine have identified a single point mutation in the normal PML gene that can block the effect of arsenic trioxide, a frontline drug for acute ...
Decitabine/cedazuridine plus venetoclax met its primary endpoint with a complete response rate of 46.5%. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA ...